Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nausea 5 Vomiting 4 Neoplasms 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Weight Loss 1 Radiation Injuries 1 Neoplasms, Germ Cell and Embryonal 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Cachexia 1 Breast Neoplasms 1 Anorexia Nervosa with Significantly Low Body Weight 1 Anorexia 1

Interventions

Trastuzumab 304 Paclitaxel 257 Cyclophosphamide 251 Docetaxel 238 Capecitabine 176 Letrozole 163 Carboplatin 163 Fulvestrant 145 Doxorubicin 145 Bevacizumab 121 Anastrozole 106 Tamoxifen 102 exemestane 94 Vinorelbine 91 Epirubicin 90 pertuzumab 89 Gemcitabine 84 Lapatinib 80 Albumin-Bound Paclitaxel 74 Radiotherapy 71 pembrolizumab 70 palbociclib 64 130-nm albumin-bound paclitaxel 58 eribulin 56 Cisplatin 55 Everolimus 49 pyrotinib 45 Taxes 44 Goserelin 43 Neoadjuvant Therapy 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × Olanzapine × Clear all

NCT04669132 2022-02-23

OLNEPA

Instituto Brasileiro de Controle do Cancer

Phase 2 Completed

Breast Neoplasms, Nausea

Data powered by HemOnc (CC BY 4.0) Colophon ⚡